Recent Finacing
Recent Raise
Aravax develops PVX108, a synthetic-peptide peanut allergy therapy undergoing Phase 2 expansion and Phase 3 preparation after Phase 1 safety and immunomodulatory results.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
